TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥18 years of age and currently receiving amifampridine phosphate for LEMS.~2. Diagnosis of LEMS by antibody testing or electromyography (EMG).~3. Completion of anti-cancer treatment at least 3 months (90 days) prior to Screening.~4. If receiving peripherally acting cholinesterase inhibitors (e.g. pyridostigmine), a stable dose of cholinesterase inhibitors is required for at least 7 days prior to randomization and throughout the study.~5. If receiving permitted oral immunosuppressants (prednisone or other corticosteroid), a stable dose is required for at least 30 days prior to randomization and throughout the study.~6. Female patients of childbearing potential must practice an effective, reliable contraceptive regimen during the study.~7. Able to perform all study procedures and assessments.~8. Willing and able to travel to study site and attend all clinic study visits.~9. Willing and able to provide written informed consent.~Exclusion Criteria:~1. Clinically significant long corrected QT (QTc) interval on ECG in previous 12 months.~2. Seizure disorder.~3. Active brain metastases.~4. Unable to ambulate.~5. Pregnant or lactating females.~6. Any other condition which, in the opinion of the Investigator, might interfere with the patient's participation in the study or confound the assessment of the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amifampridine phosphate (Type: EXPERIMENTAL): amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
- placebo (for amifampridine phosphate) (Type: PLACEBO_COMPARATOR): placebo by mouth 3 to 4 times per day for 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained by parents/legal representative (according to local regulation) prior to any study-related procedures~* Inborn and outborn, preterm neonates of either sex with a gestational age of 27 weeks up to 33 weeks+6~* Clinical and radiological findings typical of RDS~* Age on admission to the study \< 24 hours from birth~* Requirement of endotracheal intubation for surfactant administration~* Fraction of inspired oxygen (FiO2) \> 0.35 to maintain SpO2 between 90-95 %~* Documentation of normal cranial ultrasound scan~Exclusion Criteria:~* Use of surfactant prior to study entry and need for intratracheal administration of any other treatment (e.g. nitric oxide)~* Known genetic or chromosomal disorders, major congenital anomalies (cardiac malformations, myelomeningocele etc)~* Maternal drug abuse (heroin, methadone, methamphetamine, or cocaine) or significant alcohol consumption during pregnancy~* Clinical chorioamnionitis (Appendix III)~* Strong suspicion of congenital pneumonia/infection, sepsis~* Evidence of severe birth asphyxia or a 5 minutes Apgar score less / equal 3~* Presence of air leaks prior to study entry~* Neonatal seizures prior to study entry~* Mothers with prolonged rupture of the membranes (\> 3 weeks duration)~* Any condition that, in the opinion of the Investigator, would place the neonate at undue risk~* Participation in another clinical trial of any placebo, drug or biological substance conducted under the provisions of a protocol

- Gender: ALL
- Minimum Age: 27 Weeks
- Maximum Age: 34 Weeks
- Healthy Volunteers: f

Study Arms:
- Synthetic Surfactant (Type: EXPERIMENTAL): Cohort Design

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 1st cortical or subcortical unilateral infarction (supratentorial lesion)~2. Confirmed by CT or MRI~3. Subacute stage: less than 1 week~4. Moderate to severe motor function involvement-total of FMA: 0-84~5. Age: between 18 and 80 years~6. Inpatients~Exclusion Criteria:~1. Progressive or unstable stroke~2. Pre-existing and active major neurological disease~3. Pre-existing and active (e.g., on chronic medication) major psychiatric disease, such as major depression, schizophrenia, bipolar disease, or dementia~4. A history of significant alcohol or drug abuse in the prior 3 years~5. Advanced liver, kidney, cardiac, or pulmonary disease~6. A terminal medical diagnosis consistent with survival \< 1 year~7. Substantial decrease in alertness at the time of randomization, defined as score of 2 on NIH Stroke Scale~8. Pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years~9. Any condition that would represent a contraindication to Cerebrolysin, including allergy to Cerebrolysin~10. Current enrolment in another therapeutic study of stroke or stroke recovery~11. Total serum bilirubin \> 4 mg/dL, alkaline phosphatase \> 250 U/L, SGOT/AST \> 150 U/L, SGPT/ALT \> 150 U/L, or creatinine \> 3.5 mg/dL; or cardiopulmonary deficits large enough to interfere with reasonable participation in physiotherapy during the trial.~12. Previous porcine brain peptide administration history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Study Group 1 (Type: EXPERIMENTAL): Study Group 1: 30ml Cerebrolysin
- Study Group 2 (Type: PLACEBO_COMPARATOR): Study Group 2: Placebo (0.9% NaCl)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Seasonal allergic rhinitis patients out of pollen season~* Have a history and presence of birch and/or timothy grass pollen induced seasonal allergic rhinitis for at least the previous 2 years (verified by a positive skin prick test)~* Patients with need of treatment for their nasal symptoms during the pollen season~Exclusion Criteria:~* Symptomatic perennial allergic or non-allergic rhinitis~* Family history of autoimmune disease A history of asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 1. AZD8848 (Type: EXPERIMENTAL): 20 μg AZD8848 three times weekly
- 2. Placebo (Type: PLACEBO_COMPARATOR): Placebo three times weekly
- 3. AZD8848 and placebo (Type: EXPERIMENTAL): 60 μg AZD8848 once weekly and placebo twice weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SciBase International Melanoma Pivotal Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~For inclusion in the study, all subjects had to fulfill all of the following criteria:~* Men or women of any ethnic group aged ≥18 years~* Primary lesions (i.e., not metastases or recurrent lesions) that the physicians choose to excise.~* Lesion ≥ 2 mm in diameter and ≤ 20 mm in diameter~* In subjects with multiple skin lesions, all lesions destined for excision must be identified for purposes of study participation. Note: a subject may only be entered into the study once.~* The subject is willing and able to read, understand and sign the study specific informed consent form.~Exclusion Criteria:~Subjects were excluded from the study if they fulfilled any of the following criteria:~* Skin surface not measurable, e.g. lesion on a stalk~* Skin surface not accessible, e.g. inside ears, under nails~* Lesion located on acral skin, e.g. sole or palms.~* Lesion located on areas of scars, crusts, psoriasis, eczema or similar skin conditions.~* Lesion on hair-covered areas, e.g. scalp, beards, moustaches or whiskers.~* Lesion located on genitalia.~* Lesion located in an area that has been previously biopsied or subjected to any kind of surgical intervention or traumatized.~* Lesion located on mucosal surfaces.~* Skin is not intact (measurement area) e.g. bleeding or with clinical noticeable ulceration.~* Lesion with foreign matter, e.g. tattoo, splinter~* Lesion and/or reference located on acute sunburn.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SciBase III (Type: OTHER): Subjects with suspected malignant melanoma or lesions designated for total excision were included into the study. To ensure no selection bias, all eligible lesions from a subject were included into the study. All study eligible skin lesion(s) were examined with the investigational device, photographed and removed by an excisional biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized EsophyX Versus Sham / Placebo Controlled TIF Trial: The RESPECT Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80 years~* Dependent upon daily PPIs for \> 6 months~* Troublesome symptoms, specifically heartburn or regurgitation, while on 40 mg of omeprazole or equivalent.~Troublesome heartburn or regurgitation symptoms are those which occur a minimum of 2-3 days a week and are at least moderate in severity.~* Abnormal ambulatory pH study off PPI therapy for 7 days.~* Normal or near normal esophageal motility (by manometry)~* Hiatal hernia axial height is no larger than 2 cm and the transverse dimension should not exceed 2.5 cm~* Patient willing to cooperate with post-operative dietary recommendations and assessment tests~* Signed informed consent~Exclusion Criteria:~* BMI \> 35~* Hiatal hernia \> 2 cm~* Esophagitis Los Angeles grade C or D~* Esophageal ulcer~* Esophageal stricture~* Esophageal motility disorder~* Pregnancy or plans for pregnancy in the next 12 months (in females)~* Immunosuppression~* ASA \> 2~* Portal hypertension and/or varices~* History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis~* Active gastro-duodenal ulcer disease~* Gastric outlet obstruction or stenosis~* Severe gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment~* Coagulation disorders~* Interprocedural determination of anatomical presentation which in the opinion of the surgeon does not allow safe device introduction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sham placebo procedure (Type: PLACEBO_COMPARATOR): Sham Procedure: SHAM/PPI's An upper GI Endoscopy is performed with a standard endoscope, during 30-45 minutes. The patient is under general anesthesia. EGD explores the esophagus, the stomach, and the GEJ.
- TIF Transoral Fundoplication (Type: ACTIVE_COMPARATOR): Intervention: TIF 2.0/Placebo TIF Transoral Incisionless Fundoplication: A fundoplication of 270 degrees and 3cm in length was created. The EsophyX device is introduced over a standard endoscope, through the mouth, into the stomach.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of VI-0521 Compared to Placebo in Treatment of Obesity in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) ≥ 35 kg/m2~* Informed consent~* 70 years of age or less~* Triglyceride level ≤ 200 mg/dL with treatment of 0 or 1 medications~* Blood pressure of ≤ 140/90 mmHg with treatment of 0-2 medications for hypertension~* Fasting blood glucose level of ≤ 110 mg/dL~Exclusion Criteria:~* Stroke/myocardial infarction (MI)/unstable cardiovascular disease within 6 months~* Clinically significant renal, hepatic or psychiatric disease~* Unstable thyroid disease or replacement therapy~* Nephrolithiasis~* Obesity of known genetic or endocrine origin~* Participation in a formal weight loss program or lifestyle intervention~* History of glaucoma or intraocular pressure~* Pregnancy or breastfeeding~* Alcohol abuse~* Smoking cessation within previous 3 months or plans to quit smoking during study~* Eating disorders~* Cholelithiasis within past 6 months~* Excluded medications~* Type 2 diabetes~* Previous bariatric surgery~* History of bipolar disorder or psychosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VI-0521 Low (Type: EXPERIMENTAL): VI-0521; low dose phentermine/topiramate (PHEN/TPM 3.75 mg/23 mg)
- VI-0521 Top (Type: EXPERIMENTAL): Top Dose VI-0521 consisting of 15 mg of Phentermine and 92 mg of Topiramate.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Glenohumeral Osteoarthritis (OA) confirmed by radiograph~* Limitation of shoulder motion in at least one direction~* Retained active range of motion of at least 30% in all directions~Exclusion Criteria:~* Full thickness rotator cuff tear or rotator cuff tendinopathy~* Frozen shoulder~* Female who is pregnant or lactating

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supartz (Type: ACTIVE_COMPARATOR): SUPARTZ® 3 injections over 2 weeks
- Phosphate Buffered Saline (Type: PLACEBO_COMPARATOR): Phosphate Buffered Saline 3 injections over 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand and willing to comply with study procedures, restrictions, and requirements, as judged by the Investigator.~* Newly established diagnosis of WD by Leipzig-Score ≥ 4 documented by testing as outlined in 2012 European Association for the Study of the Liver Wilson Disease Clinical Practice Guidelines.~* NCC levels within or above the normal reference range (0.8 to 2.3 micromole).~* Willing to undergo 48 hour washout from current WD treatment~Exclusion Criteria:~* Treatment for greater than 24 months for WD with chelation therapy (for example, penicillamine, trientine hydrochloride) or zinc therapy.~* Decompensated hepatic cirrhosis.~* Model for End-Stage Liver Disease score \> 11.~* Modified Nazer score \> 6.~* Gastrointestinal bleed within past 6 months.~* Alanine aminotransferase \> 5 x upper limit of normal.~* Marked neurological disease requiring either nasogastric feeding or intensive in-patient medical care.~* Severe anemia with a hemoglobin \< 9 grams/deciliter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALXN1840 (Type: EXPERIMENTAL): Treatment Period: ALXN1840 at individualized doses ranging from 15 to 60 milligram (mg) per day. Dose increases or dose reductions were dependent on the individual NCC concentrations adjusted for Mo plasma concentration. ALXN1840 may have been administered every other day, once daily, or twice daily, depending on individualized dosing regimen, for 24 weeks.~Extension Period: Participants continued the same ALXN1840 daily dose maintained at Week 24 of the Treatment Period and the same dosing regimen. During the Extension Period, no up-titration was made unless NCC concentrations adjusted for Mo plasma concentration did not remain stable within (or below) the reference range. ALXN1840 could have been received for up to 36 months in the Extension Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years of age and willing to participate.~* Fluency in either English or Spanish.~* Stable patients who will undergo cardiac catheterization and PCI (intent to stent).~* Patient is willing to go on high-dose cholesterol lowering medication for the duration of the study~* Signed written Informed Consent.~* Women of childbearing potential must agree to be on an acceptable method of birth control/contraceptive such as barrier method (condoms/diaphragm); hormonal contraceptives (birth control pills, implants (Norplant) or injections (Depo-Provera)); Intrauterine Device.~* Proposed non-culprit YELLOW study lesion with max 4mm LCBI ≥ 150.~Exclusion Criteria:~* Patients who have acute myocardial infarction (ST-segment elevation presentation, new Q waves or non-ST segment elevation with CK-MB \> 5 times above the upper normal (31.5 ng/ml) within 72 hours).~* Patients who are in cardiogenic shock.~* Patients requiring coronary artery bypass graft surgery.~* Patients with platelet count \< 100,000 cell/mm3.~* Patients who have co-morbidity which reduces life expectancy to one year.~* Patients who are currently participating in another investigational drug/device study.~* Patients with liver disease.~* Patient with creatinine \> 2.0 mg/dL.~* Pregnant women and women of childbearing potential who intend to have children during the duration of the trial.~* Patients having undergone heart transplantation, or those that may undergo heart transplantation during the study period.~* Active autoimmune disease.~* Nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rosuvastatin (Type: EXPERIMENTAL): All subjects will receive rosuvastatin 40mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriasis for 6 MO~* BSA 10%~* PASI 12 or above~* PGA 3 or above~Exclusion Criteria:~* Previous exposure to either etanercept or ABT-874

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Meloxicam Capsules to Treat Osteoarthritis Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Functional Class I-III OA of the hip or knee~* Chronic user of nonsteroidal anti-inflammatory drugs (NDAIDs) and/or acetaminophen for OA pain~* Discontinued all analgesic therapy at Screening~* For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control~Exclusion Criteria:~* History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam~* Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip~* Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease~* Significant difficulties swallowing capsules or unable to tolerate oral medication~* Previous participation in another clinical study of Meloxicam Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meloxicam Test Capsules low dose QD (Type: EXPERIMENTAL): Meloxicam Test Capsules low dose QD
- Meloxicam Test Capsules high dose QD (Type: EXPERIMENTAL): Meloxicam Test Capsules high dose QD
- Placebo Capsule QD (Type: PLACEBO_COMPARATOR): Placebo Capsule QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete